XML 261 R74.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Contingent Liabilities, Commitments, Claims and Liens (Details) ₪ in Thousands, $ in Thousands |  |  |  |  | 12 Months Ended |
--- | --- | --- | --- | --- | --- | ---
Jul. 27, 2022 USD ($) | Dec. 02, 2021 USD ($) | Nov. 13, 2019 USD ($) | Apr. 11, 2017 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2023 ILS (₪)
Contingent Liabilities, Commitments, Claims and Liens [Abstract] |  |  |  |  |  |
Milestone payments, description |  |  |  |  | (i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid in cash in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating net revenues of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or the European Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company’s discretion, the respective milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are 8% for commercialization and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing from this application would likely be 2029. |
Annual investment |  |  |  |  | $ 350 |
Additional milestone amount |  |  | $ 75 |  |  |
Installment amount |  |  |  | $ 122 |  |
Estimated amount | $ 370 | $ 1,385 |  | $ 776 |  |
Capital purchase |  |  |  |  | 340,000 |
Capital warrant |  |  |  |  | $ 2,750 | ₪ 10,000,000

X
- Definition The amount of future capital expenditures that the entity is committed to make. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_CapitalCommitments
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The nominal value of capital arising from issuing ordinary shares. [Refer: Issued capital] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 78 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_IssuedCapitalOrdinaryShares
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | sprcy_AdditionalMilestoneAmount
Namespace Prefix: | sprcy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of annual investment. + References No definition available. + Details
Name: | sprcy_AnnualInvestment
Namespace Prefix: | sprcy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract
Namespace Prefix: | sprcy_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Dekel license agreement description. + References No definition available. + Details
Name: | sprcy_DekelLicenseAgreementDescription
Namespace Prefix: | sprcy_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | sprcy_EstimatedAmount
Namespace Prefix: | sprcy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of installment amount. + References No definition available. + Details
Name: | sprcy_InstallmentAmount
Namespace Prefix: | sprcy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration